RCKT News and Press, Rocket Pharmaceuticals Inc. From 08/10/23

2023-08-10 11:03:25 ET Rocket Pharmaceuticals press release ( NASDAQ: RCKT ): Q2 GAAP EPS of -$0.82 in-line. Cash, cash equivalents and investments as of June 30, 2023, were $307.0 million. For further details see: Rocket Pharmaceuticals GAAP EPS of -$0.82 in-line

Initiating enrollment of two-patient pediatric safety run-in for pivotal single-arm Phase 2 study of RP-A501 (Danon Disease); finalizing primary composite endpoint with FDA to support accelerated approval RP-L201 (LAD-I) BLA submitted to FDA; represents Rocket’s first product filin...

2023-08-03 00:42:25 ET Summary Rocket Pharmaceuticals is developing gene therapies for rare diseases, with positive results and safety profiles from clinical trials. The company's financial performance includes $360 million in cash and investments, with increased expenses and a ne...

2023-07-30 06:20:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Opportunity Fund outperformed the broader market in Q2 2023, with a 16.31% retur...

2023-07-26 07:00:00 ET Summary Baron Health Care Fund invests in companies engaged in the research, development, production, sale, delivery, or distribution of products and services related to the healthcare industry. In the quarter ended June 30, 2023, Baron Health Care Fund adva...

Shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) traded at a new 52-week high today and are currently trading at $23.63. So far today, approximately 342.95k shares have been exchanged, as compared to an average 30-day volume of 623.23k shares. Rocket Pharmaceuticals, Inc., together with ...

2023-06-08 08:38:34 ET Rocket Pharmaceuticals ( NASDAQ: RCKT ) announced Thursday that the FDA granted Fast Track and Orphan Drug designations for its gene therapy candidate RP-A601 as a treatment for the rare heart disorder, plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track and Orph...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) ...

2023-05-23 07:28:02 ET The U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to Rocket Pharmaceuticals' ( NASDAQ: RCKT ) lentiviral-based gene therapy RP-L301 to treat Pyruvate Kinase Deficiency (PKD) PKD is a rare b...